Combination therapy and future directions in renal cell carcinoma

Bernard Escudier, Camillo Porta

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Novel targeted agents have transformed the treatment of metastatic renal cell carcinoma, with significant clinical improvements compared with the previous standard of care. However, we still need to define how to use existing therapies optimally to provide maximal clinical benefit. The molecular pathways involved in the proliferation of cancer cells and tumor angiogenesis are complex. Clinical trials are currently evaluating whether therapeutic benefit can be improved by combining agents that block multiple aspects of the same or different pathways, thereby providing additive or synergistic effects. The data from combination trials to date suggest that these approaches are feasible, but all approaches tested today have been shown to be either too toxic, or currently not more active than monotherapy (may be with the exception of bevacizumab-interferon combination. This strongly suggests that combining drugs with completely different mechanisms of action. In this regards, combining VEGF-targeted therapies with new targeted immunotherapy such as ipilimumab or anti-PD 1 or PD-L1 antibodies might be the future for combination therapy in renal cell carcinoma.

Original languageEnglish
Title of host publicationTargeted Therapies for Renal Cell Carcinoma
PublisherFuture Medicine Ltd.
Pages127-142
Number of pages16
ISBN (Print)9781780840024, 9781780841014
DOIs
Publication statusPublished - Oct 1 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint

Dive into the research topics of 'Combination therapy and future directions in renal cell carcinoma'. Together they form a unique fingerprint.

Cite this